Article

Cancer Treatment Studies Abandoned Before Completion

Waste and inefficiency cited as major cause of abandonment.

The Institute of Medicine (IOM) reviewed government-funded cancer treatment research studies and determined that 40% of clinical trials are abandoned prior to completion because of waste and inefficiency. The IOM found that the National Cancer Institute's Clinical Trials Cooperative Group Program (CTCGP) consequently is unable to effectively study the benefits of new and current cancer treatments.

Recommendations include improving CTCGP efficiency and reducing the time required to design and launch clinical trials by consolidating cooperative group functions and streamlining processes. It was also recommended that scientific innovations, such as biomarkers, begin to be incorporated in study designs. Increased funding was recommended to adequately conduct studies that have the greatest likelihood of improving patients' survival and quality of life. This in turn would increase the study completion rate and allow earlier publication of study findings so they may be applied in practice. Lastly, incentives for study participation were recommended to fully cover the costs of conducting clinical trials.

The complete IOM report is available at http://books.nap.edu/openbook.php?record_id=12879.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
© 2024 MJH Life Sciences

All rights reserved.